CL2023001408A1 - Ezh2 Inhibition Therapies for Androgen Receptor Mutated Prostate Cancers - Google Patents
Ezh2 Inhibition Therapies for Androgen Receptor Mutated Prostate CancersInfo
- Publication number
- CL2023001408A1 CL2023001408A1 CL2023001408A CL2023001408A CL2023001408A1 CL 2023001408 A1 CL2023001408 A1 CL 2023001408A1 CL 2023001408 A CL2023001408 A CL 2023001408A CL 2023001408 A CL2023001408 A CL 2023001408A CL 2023001408 A1 CL2023001408 A1 CL 2023001408A1
- Authority
- CL
- Chile
- Prior art keywords
- androgen receptor
- prostate cancers
- ezh2 inhibition
- inhibition therapies
- receptor mutated
- Prior art date
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 102000001307 androgen receptors Human genes 0.000 title abstract 2
- 108010080146 androgen receptors Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- CAAWBLRXQXMGHV-UHFFFAOYSA-N 7-chloro-2-[4-(3-methoxyazetidin-1-yl)cyclohexyl]-2,4-dimethyl-N-[(6-methyl-4-methylsulfanyl-2-oxo-1H-pyridin-3-yl)methyl]-1,3-benzodioxole-5-carboxamide Chemical compound ClC1=CC(=C(C2=C1OC(O2)(C)C1CCC(CC1)N1CC(C1)OC)C)C(=O)NCC=1C(NC(=CC=1SC)C)=O CAAWBLRXQXMGHV-UHFFFAOYSA-N 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 abstract 1
- 229960004671 enzalutamide Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se proporcionan métodos para tratar el cáncer de próstata que tiene al menos una mutación AR patógena usando 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida, o una sal del mismo farmacéuticamente aceptable, solo o en combinación con una cantidad terapéuticamente efectiva de un inhibidor de la señalización del receptor de andrógenos (ARSI) tal como enzalutamida.Provided herein are methods for treating prostate cancer having at least one pathogenic AR mutation using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N -((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxol-5-carboxamide, or a salt thereof pharmaceutically acceptable, alone or in combination with a therapeutically effective amount of an androgen receptor signaling inhibitor (ARSI) such as enzalutamide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115165P | 2020-11-18 | 2020-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001408A1 true CL2023001408A1 (en) | 2024-01-12 |
Family
ID=79024100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001408A CL2023001408A1 (en) | 2020-11-18 | 2023-05-16 | Ezh2 Inhibition Therapies for Androgen Receptor Mutated Prostate Cancers |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230414593A1 (en) |
| EP (1) | EP4247371A1 (en) |
| JP (1) | JP2023549564A (en) |
| KR (1) | KR20230110527A (en) |
| CN (1) | CN116600804A (en) |
| AU (1) | AU2021382606A1 (en) |
| CA (1) | CA3199421A1 (en) |
| CL (1) | CL2023001408A1 (en) |
| IL (1) | IL303025A (en) |
| MX (1) | MX2023005840A (en) |
| WO (1) | WO2022109106A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114793A1 (en) * | 2018-04-18 | 2020-10-14 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES OF THEM |
-
2021
- 2021-11-18 WO PCT/US2021/059847 patent/WO2022109106A1/en active Application Filing
- 2021-11-18 JP JP2023529941A patent/JP2023549564A/en active Pending
- 2021-11-18 MX MX2023005840A patent/MX2023005840A/en unknown
- 2021-11-18 IL IL303025A patent/IL303025A/en unknown
- 2021-11-18 US US18/037,120 patent/US20230414593A1/en active Pending
- 2021-11-18 EP EP21827282.1A patent/EP4247371A1/en active Pending
- 2021-11-18 CA CA3199421A patent/CA3199421A1/en active Pending
- 2021-11-18 AU AU2021382606A patent/AU2021382606A1/en active Pending
- 2021-11-18 KR KR1020237017778A patent/KR20230110527A/en unknown
- 2021-11-18 CN CN202180077565.8A patent/CN116600804A/en active Pending
-
2023
- 2023-05-16 CL CL2023001408A patent/CL2023001408A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230414593A1 (en) | 2023-12-28 |
| CN116600804A (en) | 2023-08-15 |
| WO2022109106A1 (en) | 2022-05-27 |
| JP2023549564A (en) | 2023-11-27 |
| KR20230110527A (en) | 2023-07-24 |
| AU2021382606A9 (en) | 2024-08-08 |
| AU2021382606A1 (en) | 2023-06-22 |
| CA3199421A1 (en) | 2022-05-27 |
| EP4247371A1 (en) | 2023-09-27 |
| IL303025A (en) | 2023-07-01 |
| MX2023005840A (en) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220584A (en) | Fused tricyclic kras inhibitors | |
| MX2021014177A (en) | Kras g12c inhibitors and uses thereof. | |
| MY196582A (en) | PD-1/PD-L1 Inhibitors | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2018013848A (en) | Combination of anti-pd-1 antibodies and radiation to treat cancer. | |
| MX2024006123A (en) | Specific tryptamines for use in the treatment of mood disorders. | |
| ECSP066362A (en) | INHIBITORS OF MYTHOTIC KINESINE. | |
| CO2022001480A2 (en) | Inhibition of ezh2 in combination therapies for the treatment of cancer | |
| MX2023011856A (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer. | |
| MX2023011853A (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer. | |
| MX2024000357A (en) | Tricyclic compounds as inhibitors of kras. | |
| MX2019012176A (en) | Chk1 (sra737)/parpi combination methods of inhibiting tumor growth. | |
| WO2023287730A8 (en) | Tricyclic compounds | |
| CO2024009571A2 (en) | Parp1 inhibitors | |
| PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
| MX2022008099A (en) | Treatment of cancer with cdk12/13 inhibitors. | |
| CL2021001638A1 (en) | Treatment of cancer with docetaxel by controlling peak plasma levels | |
| MX2023005806A (en) | Treatment of kras mutant cancers. | |
| AR126101A1 (en) | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | |
| MX2022006853A (en) | Macrocycles for use in treating disease. | |
| MX2022004524A (en) | Gene therapy for alzheimer's disease. | |
| CL2023001408A1 (en) | Ezh2 Inhibition Therapies for Androgen Receptor Mutated Prostate Cancers | |
| MX2021015970A (en) | Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy. | |
| MX2024000406A (en) | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer. | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof |